Omni Health, Inc. Expands Scientific Advisory Boar
Post# of 617763
MIAMI, FL--(Marketwired - Jun 1, 2017) - Omni Health, Inc. (
Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors' offices and medical facilities.
Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.
The global wellness products industry is currently a $569 billion industry, and anti-aging is one of the fastest growing categories. The market research firm Global Industry Analysts estimates that a boomer fueled consumer base "seeking to keep the dreaded signs of aging at bay" will push US market for anti-aging products from about $80 billion now to more than $114 billion by 2020. Anti-aging skincare is one of the industry's booming sectors.
CEO Andrey Soloviev further noted, "Our plan for growth accelerates with the synergy created by our scientific board, our current/future product lines and our existing pharmacy which has been operating for 41 years. With Dr. Samuels' expertise, we expect to innovate, develop multiple lines of products beginning with our flagship skincare line."
For more information about Omni Health, go to www.OmniHealth.md
About Omni Health Inc.
Omni Health, Inc. (
Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
Contact: Andrey Soloviev Chief Executive Officer ceo@OmniHealth.md